NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

igc pharma
IGC Appoints Claudia Grimaldi to its Board of Directors
Read More →
igc pharma
IGC Reports Financial Results for the December 31, 2021 Quarter
Read More →
clincloud
Phase 1 Clinical Trial Data Indicate IGC’’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients
Read More →
igc pharma
IGC Form 10-Q Quarter Ended September 30, 2021
Read More →
igc-ad1 igc pharma
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability
Read More →
igc-ad1 igc pharma
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients
Read More →
igc-ad1
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
Read More →
igc pharma
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021
Read More →
clincloud
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Read More →
igc-ad1 igc pharma
IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Read More →
alzheimer igc pharma
IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain
Read More →
igc-ad1 igc pharma
Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients
Read More →
igc pharma
IGC Reports Financial Results for December 31, 2020 Quarter
Read More →
igc pharma
IGC Announces Results of its 2020 Annual Shareholders Meeting
Read More →
igc pharma
IGC Nominates Mr. John E. Lynch to Its Board of Directors
Read More →
igc pharma
IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
Read More →